Models Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The patient derived xenograft (PDX) ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

This molecule has demonstrated complete tumor regression in human xenograft models, even under aggressive growth conditions, ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

In an MTAP-deleted mouse xenograft model of non-small cell lung cancer, Apeiron found that GTA182 induced sustained tumor regression with no loss of body weight. The drug also demonstrated brain ...

Gliocidin selectively kills glioblastoma cells by inhibiting nucleotide synthesis, showing potential as a therapeutic option ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

In vivo, knock-down of CD147 in MiaPaCa2 cells by inducible short hairpin RNA (shRNA)-mediated CD147 silencing reduced invasiveness through the chorioallantoic membrane of chick embryos (CAM assay) ...

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an upcoming poster presentation on ...

In studies performed on a human lymphoma xenograft mouse model, human CD19 CAR-T cells sorted for high Golgi content or for ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...